- Cancer Genetics (CGIX +15.4%) shares spike after Aegis Capital initiates the molecular diagnostics company at Buy with an 18-month PT of $25 (potential upside of 80%).
- Analyst Raghuram Selvaraju is bullish on Cancer Genetics' "broad pipeline of tests ... both commercialized and under development, and with its ability to generate high-margin revenue from partnerships with biopharmaceutical firms that are seeking to develop theranostic solutions for patients."
- He also thinks the company's CLIA-accredited facility, which can perform a variety of advanced screens, 'provides the sort of flexibility not seen in other molecular diagnostics firms."
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs